Table 3 Representative studies evaluating 64Cu-labeled nanoparticles in preclinical cancer models
From: Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology
64Cu-labeled NPs | NPs/Chelate | Experimental contitions t (min)/T(ºC)/pH | Radiochemical yield (%) | Evaluated applications | References |
|---|---|---|---|---|---|
[64Cu]Cu-DOX-anti-PD-1-Liposomes [64Cu]Cu-PEG-Liposomes (MM-DX-929) | Liposomes/DOTA Liposomes/4-DEAP-ATSC | 2 h/43 °C/pH 6.5 1 min/25 °C/pH 6 | 62%  > 90% | PET imaging of PD-1-overexpressing breast tumors. In vitro and in vivo results of enhanced chemotherapy effects PET imaging of breast tumors | Du et al. 2017) Lee et al. 2018) |
[64Cu]Cu-AGuIX [64Cu]Cu-IR783 –AguIX | AGuIX/DOTA AGuIX/NODAGA | 1 h/37 °C/pH 5.5 45 min/37 °C/pH 5.5 |  > 98% – | PET imaging of liver cancer. Positive in vivo results of radionuclide therapy with AGuIX after irradiation using an X-ray source PET/MRI/ optical imaging of TSA tumors | Hu et al. 2017) Thakare et al. 2019) |
[64Cu]Cu-DOX-PEG-LNP [64Cu]Cu- cys-DB- PEG-LNP [64Cu]Cu-anti-CEA- PEG-DBCO LND | LNP/DOTA LND/DOTA | 45 min/43 °C/pH 5.5 – |  > 75% 70% | PET imaging of prostate cancer. In vivo results of enhanced chemotherapy effects PET imaging by targeting carcinoembryonic antigen (CEA) in breast cancer | Wong et al. 2017) Wong et al. 2020) |
[64Cu]Cu-PEG-Fe-GA-CPNs | Fe-GA-CPNs/chelate-free | 60 min/37 °C/pH 5.5 | 75% | PET imaging and photoacoustic tomography/MRI of breast cancer. In vitro and in vivo results of photothermal therapy | Jin et al. 2017) |
[64Cu]Cu-Macrin | Macrin/NODAGA | 30 min/90 °C/pH 6 |  > 99% | PET and optical imaging of tumor-associated macrophages in lung carcinoma | Kim et al. 2018) |
[64Cu]Cu-SiGdNP | SiGdNP/NODAGA | 30 min/37 °C/pH 5.8 | No reported | PET/MRI dual imaging of metastatic mammary adenocarcinoma (TS/A) | Tran et al. 2018) |
[64Cu]Cu-PEG-dopamine-RGD-MnFe2O4 | MnFe2O4/DOTA | 40 min/50 °C/pH 6.5 | 65% | PET/MRI dual imaging by targeting integrin α(v)β(3) in glioblastoma | Shi and Shen 2018) |
[64Cu]Cu-silicon [64Cu]Cu-CQDs | Silicon and CQDs /NOTA | 30 min/25 °C/pH 6 |  > 99% | PET imaging of epidermoid carcinoma | Licciardello et al. 2018) |
[64Cu]CuS-PEG-RGD [64Cu]CuS-PEG-bombesin [64Cu]CuS-PEG | CuS/chelate-free CuS/chelate-free CuS/chelate-free | 15 min/95 °C 15 min/65 °C/pH 9 15 min/95 °C |  > 98%  > 98% | PET imaging by targeting integrin α(v)β(3) in glioblastoma. In vitro and in vivo results of photothermal therapy PET imaging by GRPr in prostate cancer PET imaging of melanoma and ovarian cancer. In vitro and in vivo results of photothermal therapy combined with immunotherapy | Cui et al. 2018) Cai et al. 2018) Cao et al. 2020) |
[64Cu]Cu-GE11-micelles | Micelles/NOTA | 15 min/37 °C/pH 5.5 | 23% | PET imaging by targeting the epidermal growth factor receptor in colon cancer | Paiva et al. 2020) |
[64Cu]Cu-PEG- melanin | Melanin/chelate-free | 1 h/40 °C/pH 5.5 | – | PET imaging of epidermoid carcinoma. In vivo results of radionuclide therapy | Zhou et al. 2020) |
[64Cu]Cu-UPS polymers | UPS polymers/NOTA | 15 min/37 °C/pH 6.5 |  > 95% | PET imaging of small occult tumors in the brain, head, neck and breast of mice by targeting tumor-acidosis | Huang et al. 2020) |
[64Cu]Cu-PEG-PPa-Trp2 | Trp2 peptide-coassembled NPs /chelate-free | 30 min/25 °C |  > 97% | PET imaging of melanoma. In vivo results of dendritic cell-based immunotherapy | He et al. 2021) |